Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 9332606886 ⟟ Call Me For G...
Advances for Non Small cell Lung Cancer
1. New and Improved Targeted Therapies for
NSCLCs
William N. William Jr.
Assistant Professor
Chief, Head and Neck Section
Department of Thoracic / Head and Neck Medical Oncology
M. D. Anderson Cancer Center
9. Selective EGFR TKIs: Conclusions
• High response rates and extended PFS after failure
of first-generation EGFR TKIs
• Higher response rates in T790M+
• Toxicity patterns consistent with selectivity to
mutant receptors
10. Shepherd et al. N Engl J Med. 2005;353:123.
Adenocarcinomas
Targeted agents for driver molecular alterations
17. Ceritinib in ALK+ Patients
Shaw A et al. NEJM 2014
Response rates:
• 56% crizotinib-treated patients
• 62% crizotinib-naïve patients
Response rates:
• 86% ALK-dependant resistance
• 59% non ALK-dependant resistance
18.
19. ALK Inhibitors: Conclusions
• Crizotinib improves PFS over pemetrexed/platinum in
treatment-naïve ALK+ patients
• Crizotinib improves response rates, PFS and QoL over
pemetrexed or docetaxel in previously treated ALK+
patients. No improvements on premature analysis of
OS, in the setting of high crossover rate (64%)
• Pemetrexed has better response rates and PFS
compared to docetaxel in ALK+ patients
• Second generation ALK inhibitors have high response
rates in crizotinib-naïve and crizotinib-treated patients,
including responses in the brains
• Best strategy as regards to sequencing of ALK inhibitors
and chemotherapy to be determined
20. Shepherd et al. N Engl J Med. 2005;353:123.
Adenocarcinomas
Targeted agents for driver molecular alterations
39. Targeted Agents for Driver Molecular
Alterations
• Crizotinib is active in ROS-1 positive tumors
• Dabrafenib is active in patients with a BRAF V600E activating
mutation
• Dasatinib may be active in patients with a BRAF inactivating
mutation
• MEK inhibitors with modest activity in difficult to treat, KRAS
positive patients
• Preliminary evidence of activity of HER-2 targeting with
trastuzumab, afatinib, but not lapatinib, in HER-2 mutant
tumors
• Cabozantinib may be active in RET positive tumors
• Metmab + erlotinib may improve PFS and OS comapred to
erlotinib in MET positive patients. Phase III results pending.
41. Squamous Cell Carcinomas
Targeted agents for driver molecular alterations
Shepherd et al. N Engl J Med. 2005;353:123.
Paik et al. ASCO 2013
42. Take Home Messages
• Treatment with agents targeting driver
alterations may result in promising activity
for molecularly-defined subgroups of
patients
• Targetable mutations more frequently
identified in adenocarcinomas, compared to
squamous cell carcinomas
• Precision medicine for NSCLC treatment is
here to stay